{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:36:03Z","timestamp":1790760963660,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jchf.2020.03.007","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T16:19:37Z","timestamp":1594225177000},"page":"701-711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Utility of Biomarkers in Cardiac Amyloidosis"],"prefix":"10.1016","volume":"8","author":[{"given":"Arianna","family":"Pregenzer-Wenzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Barrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Kovacsovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2020.03.007_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.03.007_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12383","article-title":"Cardiac amyloidosis: where are we today?","volume":"278","author":"Patel","year":"2015","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jchf.2020.03.007_bib3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/01.CIR.102.11.1216","article-title":"It's time for a change to a troponin standard","volume":"102","author":"Jaffe","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.03.007_bib4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2020.03.007_bib5","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.03.007_bib6","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2020.03.007_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light\u00a0chain amyloidosis incorporating cardiac biomarkers and serum free light chain\u00a0measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2020.03.007_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.18.01398","article-title":"Validation of Mayo Clinic staging system for light chain amyloidosis with high-sensitivity troponin","volume":"37","author":"Kumar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2020.03.007_bib9","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jchf.2020.03.007_bib11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","article-title":"Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia","volume":"104","author":"Dittrich","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jchf.2020.03.007_bib12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild\u2013type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2020.03.007_bib13","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2020.03.007_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2020.03.007_bib15","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2012.192716","article-title":"Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population","volume":"58","author":"Apple","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.jchf.2020.03.007_bib16","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jchf.2020.03.007_bib17","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jchf.2020.03.007_bib18","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib19","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2020.03.007_bib21","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2020.03.007_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/postgradmedj-2014-133224","article-title":"The transthyretin amyloidoses: advances in therapy","volume":"91","author":"Dubrey","year":"2015","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jchf.2020.03.007_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Castano","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.jchf.2020.03.007_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long\u2013term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2020.03.007_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jchf.2020.03.007_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2020.03.007_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2020.03.007_bib28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.03.007_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2020.03.007_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004802","article-title":"Serum transthyretin: predictor of amyloidosis outcomes?","volume":"11","author":"Nativi-Nicolau","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"Suppl 1","key":"10.1016\/j.jchf.2020.03.007_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2020.03.007_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","author":"Wixner","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2020.03.007_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.03.007_bib34","first-page":"431","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study","volume":"139","author":"Scott","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.03.007_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","article-title":"Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/13506129.2011.627069","article-title":"Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis","volume":"18","author":"Palladini","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2020.03.007_bib37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.306.306","article-title":"Growth differentiation factor-15 in patients with light chain (AL) amyloidosis has independent prognostic significance and adds prognostic information related to risk of early death and renal outcomes","volume":"124","author":"Kastritis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib38","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/13506129.2014.940457","article-title":"Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis","volume":"21","author":"Kristen","year":"2014","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2020.03.007_bib40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.24001","article-title":"Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jchf.2020.03.007_bib41","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1038\/bcj.2015.45","article-title":"Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging","volume":"5","author":"Kastritis","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jchf.2020.03.007_bib42","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2010-02-267708","article-title":"Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay","volume":"116","author":"Kristen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","article-title":"High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis","volume":"100","author":"Dispenzieri","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2020.03.007_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","article-title":"Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition","volume":"1","author":"Biolo","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2020.03.007_bib45","article-title":"Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis","volume":"2","author":"Tanaka","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2020.03.007_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2017","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2020.03.007_bib47","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/13506129.2016.1242480","article-title":"Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis","volume":"23","author":"Swiger","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2020.03.007_bib48","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2020.03.007_bib49","doi-asserted-by":"crossref","first-page":"E506","DOI":"10.1002\/ajh.24563","article-title":"Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid\u2013directed monoclonal antibody","volume":"91","author":"Gertz","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jchf.2020.03.007_bib50","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ijcard.2014.07.106","article-title":"Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis","volume":"176","author":"Kristen","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2020.03.007_bib51","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2020.03.007_bib52","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/ajh.23936","article-title":"Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients\u00a0treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies","volume":"90","author":"Kastritis","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jchf.2020.03.007_bib53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.03.007_bib54","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2016.1221815","article-title":"Identification of prognostic markers in transthyretin and AL cardiac amyloidosis","volume":"23","author":"Damy","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jchf.2020.03.007_bib55","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2459\/JCM.0000000000000349","article-title":"Different NT-proBNP circulating levels for different types of cardiac amyloidosis","volume":"17","author":"Perfetto","year":"2016","journal-title":"J\u00a0Cardiovasc Med"},{"key":"10.1016\/j.jchf.2020.03.007_bib56","doi-asserted-by":"crossref","first-page":"e0173086","DOI":"10.1371\/journal.pone.0173086","article-title":"Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis---report\u00a0from the Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"12","author":"Kristen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2020.03.007_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00392-017-1167-1","article-title":"Predictors of survival stratification in patients with wild-type cardiac amyloidosis","volume":"107","author":"Siepen","year":"2017","journal-title":"Clin Res Cardiol"}],"updated-by":[{"DOI":"10.1016\/j.jchf.2020.10.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000}}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177920302031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177920302031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:32:11Z","timestamp":1636158731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177920302031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2213177920302031"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2020.03.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of Biomarkers in Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2020.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}